The 2022 revision of the PIC/S Guide to GMP for Medicinal Products (PE 009-17) Annex 1 is expected to be adopted by the Therapeutic Goods Administration (TGA) in 2025 and Contamination Control Strategy (CCS) has emerged as a key new requirement. While CCS under Annex 1 is central for sterile drug manufacturers, it is also applicable for...
Charles River is a global leader in providing products and services that support pharmaceutical and biotechnology companies, government agencies, and academic institutions in accelerating research and drug development. With a presence in over 150 facilities across 21 countries, Charles River has a longstanding history of contributing to the...
When manufacturing pharmaceuticals, the risk of contaminants impacting pharmaceutical safety, efficacy and purity is real.
Copyright © SeerPharma
